How do I get compassionate use access for Neuroendocrine Tumors drugs not yet approved

Compassionate Use Access for Neuroendocrine Tumor Drugs

I understand you're looking for ways to access experimental treatments for neuroendocrine tumors (NETs) when standard options aren't working. This is an important question, and there are several pathways to explore.

What Is Compassionate Use?

Compassionate use (also called "expanded access" or "right to try") allows patients with serious conditions to access investigational drugs outside of clinical trials when no approved alternatives are available. It's designed for situations where a patient has exhausted standard treatment options.

Main Pathways to Explore

1. Expanded Access Program (EAP) Through the FDA

This is the most formal route:

• How it works: Your oncologist submits a request to the drug manufacturer and FDA on your behalf

• Requirements: You typically need to show:

  • A serious or life-threatening condition
  • No comparable approved alternatives available
  • Potential benefit that outweighs risks
  • Inability to participate in a clinical trial

• Timeline: Can take weeks to months for approval

• Cost: Manufacturers may provide drugs free, but you may pay for administration and monitoring

2. Right to Try Laws

Some states have "Right to Try" laws that may allow faster access:

• Allows access to drugs in Phase 1, 2, or 3 clinical trials
• Bypasses some FDA requirements
• Varies significantly by state
• Your doctor can help determine if you qualify

3. Clinical Trials (Often Overlooked)

According to the NCCN Guidelines for Neuroendocrine Tumors, clinical trials are listed as preferred options for many NET patients, especially those with:

• Advanced or metastatic disease
• Disease progression on standard treatments
• Well-differentiated Grade 3 NETs
• Poorly differentiated neuroendocrine carcinomas

Clinical trials may offer:

• Access to newer drugs before FDA approval
• Close medical monitoring
• No cost for the investigational drug
• Potential benefit with less bureaucracy than compassionate use

---

Specific Considerations for NETs

Based on NCCN Guidelines, several drug categories are being studied for NETs:

Targeted Therapies Being Researched:

• Cabozantinib - now FDA-approved for advanced NETs (was recently approved based on clinical trial data)
• PRRT (Peptide Receptor Radionuclide Therapy) with lutetium Lu-177 dotatate - for SSTR-positive tumors
• Immunotherapy combinations - nivolumab + ipilimumab for certain NET types
• mTOR inhibitors - everolimus (approved) and others in development
• Chemotherapy combinations - various regimens being studied

---

Steps to Take Right Now

1. Talk with Your Oncologist

• Ask specifically: "Are there any clinical trials I might qualify for?"
• Discuss your disease characteristics (grade, biomarkers, SSTR status, etc.)
• Ask if they think expanded access is appropriate for your situation

2. Search for Clinical Trials

• ClinicalTrials.gov - Search "neuroendocrine tumor" + your specific type
• Cancer.gov - NCI's clinical trial finder
• Your hospital's research department - May have trials you don't know about

3. Contact NET-Specific Organizations

• Neuroendocrine Cancer Network (NECN)
• Neuroendocrine Tumor Research Foundation (NETRF)
• These organizations often have resources about accessing new treatments

4. If Clinical Trials Aren't Available

• Ask your oncologist to contact the drug manufacturer directly
• Manufacturer medical liaisons can discuss expanded access options
• Your doctor will need to prepare a detailed medical justification

5. Consider a Second Opinion

• A NET specialist at a major cancer center may know about trials or expanded access programs you haven't heard about
• Some institutions have more experience with compassionate use requests

---

Important Realities to Understand

✅ What helps your case:

• Clear documentation that standard treatments aren't working
• Evidence the experimental drug might help your specific NET type
• Good overall health status (you need to be well enough to tolerate treatment)
• A committed oncologist willing to advocate for you

⚠️ What makes it harder:

• Manufacturers are more likely to approve for drugs close to FDA approval
• Very early-stage drugs (Phase 1) are rarely approved for compassionate use
• The process takes time—weeks to months
• There's no guarantee of approval or benefit

---

Questions to Ask Your Oncologist

1. "Are there any clinical trials for my specific NET type and stage that I might qualify for?"

2. "Based on my tumor characteristics (grade, biomarkers, SSTR status), what drugs in development might be most relevant?"

3. "If clinical trials aren't available, would you be willing to pursue an expanded access request? For which drug?"

4. "Should I get a second opinion from a NET specialist about treatment options?"

5. "Are there any patient advocacy organizations that help with access to experimental treatments?"

6. "What's the timeline if we pursue expanded access—how long would it take?"

---

Additional Resource

The CancerPatientLab webinar "What Should I Do about My Neuroendocrine Cancer?" (referenced in your guidelines) discusses real patient experiences navigating advanced NET treatment options and decision-making with medical teams. This may provide helpful perspective on how other patients have approached similar situations.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.